ReviewAntibiotics (Basel, Switzerland)2018
Epidemiological Trends of Antibiotic Resistant Gonorrhoea in the United Kingdom.
Review in Antibiotics (Basel, Switzerland), 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 2 syntheses or guidelines pooled it, 48 citations in OpenAlex.
- Pooled it
- Variation in approaches to antimicrobial use surveillance in high-income secondary care settings: a systematic review.The Journal of antimicrobial chemotherapy · 2021Pooled it
- An open-label, parallel-group, randomised controlled trial of antiseptic mouthwash versus antibiotics for oropharyngeal gonorrhoea treatment (OMEGA2).Scientific reports · 2020Trial
- Trial
- Evidence for a Constrained Mutational Pathway to High-Level Spectinomycin Resistance inInternational journal of molecular sciences · 2026Article
- Investigating the Antimicrobial Efficacy of Cannabinoids and Their Derivatives AgainstBiology · 2025Article
- Modeling gonorrhea vaccination to find optimal targeting strategies that balance impact with cost-effectiveness.NPJ vaccines · 2025Article
- Cost-effectiveness of 4CMenB Vaccination Against Gonorrhea: Importance of Dosing Schedule, Vaccine Sentiment, Targeting Strategy, and Duration of Protection.The Journal of infectious diseases · 2025Article
- Short-Chained Linear Scorpion Peptides: A Pool for Novel Antimicrobials.Antibiotics (Basel, Switzerland) · 2024Review
- Projecting the development of antimicrobial resistance in Neisseria gonorrhoeae from antimicrobial surveillance data: a mathematical modelling study.BMC infectious diseases · 2023Article
- The potential public health impact of adolescent 4CMenB vaccination on Neisseria gonorrhoeae infection in England: a modelling study.BMC public health · 2023Article
- Public health impact and cost-effectiveness of gonorrhoea vaccination: an integrated transmission-dynamic health-economic modelling analysis.The Lancet. Infectious diseases · 2022Article
- Prediction of antimicrobial minimal inhibitory concentrations forSaudi journal of biological sciences · 2022Article
- Increasing Azithromycin Resistance in Neisseria gonorrhoeae Due to NG-MAST 12302 Clonal Spread in Canada, 2015 to 2018.Antimicrobial agents and chemotherapy · 2022Article
- NamBio · 2020Article
- Assessment of the Potential of Vaccination to Combat Antibiotic Resistance in Gonorrhea: A Modeling Analysis to Determine Preferred Product Characteristics.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2020Article
- Utility of MALDI-TOF MS for differentiation of Neisseria gonorrhoeae isolates with dissimilar azithromycin susceptibility profiles.The Journal of antimicrobial chemotherapy · 2020Article
- Azithromycin susceptibility ofThe Lancet. Microbe · 2020Article
- Targeted surveillance strategies for efficient detection of novel antibiotic resistance variants.eLife · 2020Article
- Synthesis and Antichlamydial Activity of Molecules Based on Dysregulators of Cylindrical Proteases.Journal of medicinal chemistry · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 3 institutions in 1 country.
Funding
Abstract
Gonorrhoea is one of the most common sexually-transmitted bacterial infections, globally and in the United Kingdom. The levels of antibiotic resistance in gonorrhoea reported in recent years represent a critical public health issue. From penicillins to cefixime, the gonococcus has become resistant to all antibiotics that have been previously used against it, in each case only a matter of years after introduction as a first-line therapy. After each instance of resistance emergence, the treatment recommendations have required revision, to the point that only a few antibiotics can reliably be prescribed to treat infected individuals. Most countries, including the UK, now recommend that gonorrhoea be treated with a dual therapy combining ceftriaxone and azithromycin. While this treatment is still currently effective for the vast majority of cases, there are concerning signs that this will not always remain the case, and there is no readily apparent alternative. Here, we review the use of antibiotics and epidemiological trends of antibiotic resistance in gonorrhoea from surveillance data over the past 15 years in the UK and describe how surveillance could be improved.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.